Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.
伊利诺伊州威尔梅特，2024年4月18日（GLOBE NEWSWIRE）——专注于为癌症患者开发创新疗法的临床阶段生物制药公司Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）今天宣布，其放射性药物项目mnPR-101-ZR（与锆89偶联的 MNPR-101）的临床前数据摘要已提交给协会核医学与分子成像（SNMMI）2024年年会已入选演讲。在加拿大多伦多举行的SNMMI 2024被公认为放射性药物领域首屈一指的教育、科学和研究活动。
Meeting Details:
会议详情：
Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting
活动：核医学与分子影像学会 (SNMMI) 2024 年年会
Date: June 8 – June 11, 2024
日期：2024 年 6 月 8 日至 6 月 11 日
Location: Metro Toronto Convention Centre, Toronto, ON, Canada
地点：加拿大安大略省多伦多市大多伦多会议中心
About Monopar Therapeutics Inc.
关于 Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: and ir.monopartx.com/presentations.
Monopar Therapeutics是一家临床阶段的生物制药公司，专注于为癌症患者开发创新疗法。Monopar 的产品线包括用于治疗各种晚期癌症的放射性药物的 1 期 MNPR-101；用于治疗晚期软组织肉瘤的 1b 期 camsirubicin；以及早期的 camsirubicin 类似物 MNPR-202。欲了解更多信息，请访问： 和 ir.monopartx.com/presentations。
CONTACT:
联系人：
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Monopar Therapeutics Inc.
投资者关系
金·土本博士
首席财务官
kimtsu@monopartx.com
Follow Monopar on social media for updates:
请在社交媒体上关注 Monopar 获取最新消息：
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
推特： @MonoparTx 领英： Monopar 疗法